IWAA 2021 23rd Annual Scientific Session
This activity is designed to allow learners to continue exploring the immunology frontier.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Intermountain West Allergy Association (IWAA). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 13 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Allied health professionals
Upon completion of this activity the participant should be able to:
1. Summarize recent data, expert opinion and clinical practice guidelines on the treatment of allergic and immunological disease.
2 Describe the safety and efficacy profiles of established and emerging therapies for the treatment of allergic and immunological diseases.
3. Apply knowledge of the pathophysiology of allergic and immunological diseases to clinical decision-making.
Jonathan Bernstein, M.D.
Advisor, Speaker, Ind Contractor – AstraZeneca, Genentech, Novartis, Sanofi Regeneron Speaker, Ind Contractor – GSK
Carla Davis, M.D.
Researcher – Allergenis, DBV Technologies, Therapeutics, Nestle, Inc, Regeneron
Matthew Greenhawt, M.D.
Advisor – ALK-Abello, AllerGenis, Allergy Therapeutics, Aravax, DBV, Genentech, GSK, Merck, Novartis, Nutricia, Pfizer, Prota, Sanofi, USWorldMeds,
Advisor, Speaker – Aquestive
Melinda Rathkopf, M.D.
Speaker – Teva
Andrew White, M.D.
Advisor – ALK, Blueprint Pharmaceuticals, Genentech
Advisor, Speaker – AstraZeneca, GSK, Optinose, Sanofi/Regeneron
Carl Thornblade, M.D.
Contracted Research – AstraZeneca, Bayer, Bellus, Bond Avillion 2 Development, Galderma, Leo Pharma, Novartis, Regeneron, Sanofi-Aventis, Satsuma, Shionogi, Teva, Verona
The following have no relevant financial relationships to disclose:
Ronald England, M.D.
Richard Henry, M.D.
John Kelso, M.D.
Jennifer Kuehn, CPC
Karina Serban, M.D.
Carl Thornblade, M.D.
Jim Thompson, Ph.D.
Gregory Wickern, M.D.
- 14.50 AMA PRA Category 1 Credit™
- 14.50 Attendance